Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens.

by Aparna Vasanthakumar, Justin W Davis, Manal Abunimeh, Jonas Söderholm, Jiuhong Zha, Emily O Dumas, Daniel E Cohen, Jeffrey F Waring, Martin Lagging
Published 2018-01-01

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease

by David E. Bernstein, Albert Tran, Paul Martin, Kris V. Kowdley, Marc Bourliere, Mark S. Sulkowski, Paul J. Pockros, Boris Renjifo, Deli Wang, Diana L. Shuster, Daniel E. Cohen, Ira M. Jacobson
Published 2019-02-01

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease

by Eric Lawitz, Edward Gane, Eric Cohen, John Vierling, Kosh Agarwal, Tarek Hassanein, Parvez S. Mantry, Paul J. Pockros, Michael Bennett, Nyingi Kemmer, Giuseppe Morelli, Jiuhong Zha, Deli Wang, Nancy S. Shulman, Daniel E. Cohen, K. Rajender Reddy
Published 2019-02-01

Parabacteroides distasonis: intriguing aerotolerant gut anaerobe with emerging antimicrobial resistance and pathogenic and probiotic roles in human health

by Jessica C. Ezeji, Daven K. Sarikonda, Austin Hopperton, Hailey L. Erkkila, Daniel E. Cohen, Sandra P. Martinez, Fabio Cominelli, Tomomi Kuwahara, Armand E. K. Dichosa, Caryn E. Good, Michael R. Jacobs, Mikhail Khoretonenko, Alida Veloo, Alexander Rodriguez-Palacios
Published 2021-01-01

Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection.

by Marylyn M Addo, Rika Draenert, Almas Rathod, Cori L Verrill, Benjamin T Davis, Rajesh T Gandhi, Gregory K Robbins, Nesli O Basgoz, David R Stone, Daniel E Cohen, Mary N Johnston, Theresa Flynn, Alysse G Wurcel, Eric S Rosenberg, Marcus Altfeld, Bruce D Walker
Published 2007-03-01

Grapevine leafroll-associated virus 3

by Hans J. Maree, Hans J. Maree, Rodrigo P. P. Almeida, Rachelle eBester, Kar Mun eChooi, Daniel eCohen, Valerian V. Dolja, Marc F. Fuchs, Deborah A. Golino, Anna E. C. Jooste, Giovanni P. Martelli, Rayapati A. Naidu, Adib eRowhani, Pasquale eSaldarelli, Johan eBurger
Published 2013-04-01

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4

by Daniel H. Leung, Stefan Wirth, Betty B. Yao, Rolando M. Viani, Regino P. Gonzalez‐Peralta, Maureen M. Jonas, Steven J. Lobritto, Michael R. Narkewicz, Etienne Sokal, Clàudia Fortuny, Evelyn K. Hsu, Antonio Del Valle‐Segarra, Jiuhong Zha, Lois Larsen, Li Liu, Diana L. Shuster, Daniel E. Cohen, Philip Rosenthal
Published 2018-11-01

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis

by Mario G. Pessoa, José V. Ramalho-Madruga, Katia Alves, Estevão P. Nunes, Hugo Cheinquer, Carlos E. Brandão-Mello, Maria C. Mendes-Correa, Maria L. Ferraz, Paulo R.A. Ferreira, Mário R. Álvares-da-Silva, Henrique S. Coelho, Evaldo S. Affonso-de-Araújo, Juvencio Furtado, Raymundo Parana, Giovanni Silva, Sara A. Lari, Li Liu, Rakesh Tripathi, Tami Pilot-Matias, Daniel E. Cohen, Nancy S. Shulman, Ana Martinelli
Published 2018-11-01